Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans

Thyroid

Volumn 21, Issue 11, 2011, Pages 1227-1234

  Landriscina, Matteo ^a,b   Pannone, Giuseppe ^a   Piscazzi, Annamaria ^a   Toti, Paolo ^c   Fabiano, Annarita ^a   Tortorella, Simona ^a   Occhini, Rossella ^c   Ambrosi, Antonio ^a   Bufo, Pantaleo ^a   Cignarelli, Mauro ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MOLECULAR MARKER; THYROTROPIN;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID CARCINOMA; THYROID TUMOR; TUMOR CELL; TUMOR DIFFERENTIATION; UNDIFFERENTIATED THYROID CARCINOMA; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CELL DEDIFFERENTIATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 83755206271     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0172     Document Type: Article

References (27)

1. Riesco-Eizaguirre G, Santisteban P 2007 New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer 14:957-977. (Pubitemid 351252429)
2. Patel KN, Shaha AR 2006 Poorly differentiated and ana-plastic thyroid cancer. Cancer Control 13:119-128.
3. Kinder BK 2003 Well differentiated thyroid cancer. Curr Opin Oncol 15:71-77. (Pubitemid 36135651)
4. Are C, Shaha AR 2006 Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453-464.
5. Vasko VV, Saji M 2007 Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. Curr Opin Oncol 19:11-17. (Pubitemid 44885594)
6. Landriscina M, Piscazzi A, Fabiano A, Maddalena F, Cost-antino E, Farese A, Bufo P, Cignarelli M 2009 Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype. Thyroid 19:629-637.
7. Ferguson KM 2008 Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 37:353-373.
8. Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Mitsiades N 2006 Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 91:3662-3666. (Pubitemid 44402152)
9. Lee DH, Lee GK, Kong SY, Kook MC, Yang SK, Park SY, Park SH, Keam B, Park do J, Cho BY, Kim SW, Chung KW, Lee ES, Kim SW 2007 Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol 60:881-884. (Pubitemid 47234434)
10. Masago K, Asato R, Fujita S, Hirano S, Tamura Y, Kanda T, Mio T, Katakami N, Mishima M, Ito J 2009 Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer 124:2744-2749.
11. DeLellis RA, Lloyd RV, Heitz PU, Eng C 2004 Pathology and Genetics of Tumours of Endocrine Organs. IARC Press, Lyon.
12. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M 2002 American Joint Committee on Cancer. Cancer Staging Manual, 6th ed. Springer, New York.
13. Goldstein NS, Armin M 2001 Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon ade-nocarcinoma: implications for a standardized scoring system. Cancer 92:1331-1346.
14. Hynes NE, MacDonald G 2009 ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21:177-184.
15. Dei Tos AP 2007 The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. Int J Biol Markers 22(1 Suppl 4):S3-S9. (Pubitemid 46730018)
16. Ensinger C, Spizzo G, Moser P, Tschoerner I, Prommegger R, Gabriel M, Mikuz G, Schmid KW 2004 Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann N Y Acad Sci 1030:69-77. (Pubitemid 40378898)
17. Murakawa T, Tsuda H, Tanimoto T, Tanabe T, Kitahara S, Matsubara O 2005 Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for new therapeutic approach. Pathol Int 55:757-765. (Pubitemid 43110201)
18. Lim DJ, Baek KH, Lee YS, Park WC, Kim MK, Kang MI, Jeon HM, Lee JM, Yun-Cha B, Lee KW, Son HY, Kang SK 2007 Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma. Thyroid 17:883-888.
19. Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Sil-verman JS 2009 Targeting EGFR resistance networks in head and neck cancer. Cell Signal 21:1255-1268.
20. Nucera C, Lawler J, Parangi S 2011 BRAF(V600E) and mi-croenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res 71:2417-2422.
21. Liu ZM, Wu TT, van Hasselt CA, Chen GG 2010 Carcino-genesis and therapeutic strategies in thyroid cancer. Curr Drug Targets 11:716-732.
22. Grodski S, Delbridge L 2009 An update on papillary mi-crocarcinoma. Curr Opin Oncol 21:1-4.
23. Ciardiello F, Tortora G 2008 EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174.
24. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ 2008 A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18:317-323. (Pubitemid 351415790)
25. Nobuhara Y, Onoda N, Yamashita Y, Yamasaki M, Ogisawa K, Takashima T, Ishikawa T, Hirakawa K 2005 Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 92: 1110-1116. (Pubitemid 40546677)
26. Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, Milas ZL, Galer CE, Henderson YC, Jasser SA, Schwartz DL, Bankson JA, Myers JN, Lai SY 2011 Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of ana-plastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 17:2281-2291.
27. Landriscina M, Maddalena F, Fabiano A, Piscazzi A, La Macchia O, Cignarelli M 2010 Erlotinib enhances the proa-poptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. Anticancer Res 30:473-480.